 | • レポートコード：MRC2-11QY04557 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は強皮症診断・治療のグローバル市場について調査・分析したレポートです。種類別（コルチコステロイド、免疫抑制剤、エンドセリン受容体作動薬、カルシウムチャネル遮断薬、PDE-5阻害薬、キレート剤、プロスタサイクリン類似体、その他（H2遮断薬、プロトンポンプ阻害薬、ACE阻害薬、その他））市場規模、用途別（皮膚生検、画像技術、血液検査、心電図および心エコー検査、肺機能検査）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別強皮症診断・治療の競争状況、市場シェア ・世界の強皮症診断・治療市場：種類別市場規模 2015年-2020年（コルチコステロイド、免疫抑制剤、エンドセリン受容体作動薬、カルシウムチャネル遮断薬、PDE-5阻害薬、キレート剤、プロスタサイクリン類似体、その他（H2遮断薬、プロトンポンプ阻害薬、ACE阻害薬、その他）） ・世界の強皮症診断・治療市場：種類別市場規模予測 2021年-2026年（コルチコステロイド、免疫抑制剤、エンドセリン受容体作動薬、カルシウムチャネル遮断薬、PDE-5阻害薬、キレート剤、プロスタサイクリン類似体、その他（H2遮断薬、プロトンポンプ阻害薬、ACE阻害薬、その他）） ・世界の強皮症診断・治療市場：用途別市場規模 2015年-2020年（皮膚生検、画像技術、血液検査、心電図および心エコー検査、肺機能検査） ・世界の強皮症診断・治療市場：用途別市場規模予測 2021年-2026年（皮膚生検、画像技術、血液検査、心電図および心エコー検査、肺機能検査） ・北米の強皮症診断・治療市場分析：米国、カナダ ・ヨーロッパの強皮症診断・治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの強皮症診断・治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の強皮症診断・治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの強皮症診断・治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Actelion Pharmaceuticals, Inc.、Boehringer Ingelheim、Bayer AG、Cytori Therapeutics, Inc.、Cumberland Pharmaceuticals Inc、Gilead Sciences, Inc.、Pfizer, Inc.、Sanofi、Corbus Pharmaceutical Holdings, Inc.、F. Hoffmann La Roche Ltd.、Merck KGaA ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Scleroderma Diagnostics and Therapeutics Market
The global Scleroderma Diagnostics and Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Scleroderma Diagnostics and Therapeutics Scope and Market Size
Scleroderma Diagnostics and Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Scleroderma Diagnostics and Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim
Bayer AG
Cytori Therapeutics, Inc.
Cumberland Pharmaceuticals Inc
Gilead Sciences, Inc.
Pfizer, Inc.
Sanofi
Corbus Pharmaceutical Holdings, Inc.
F. Hoffmann La Roche Ltd.
Merck KGaA
Market segment by Type, the product can be split into
Corticosteroids
Immunosuppressive Agents
Endothelin Receptor Agonists
Calcium Channel Blockers
PDE-5 Inhibitors
Chelating Agents
Prostacyclin Analogues
Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
Market segment by Application, split into
Skin Biopsy
Imaging Techniques
Blood Tests
Electrocardiogram and Echocardiogram
Pulmonary Function Tests
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Scleroderma Diagnostics and Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Scleroderma Diagnostics and Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Corticosteroids
1.4.3 Immunosuppressive Agents
1.4.4 Endothelin Receptor Agonists
1.4.5 Calcium Channel Blockers
1.4.6 PDE-5 Inhibitors
1.4.7 Chelating Agents
1.4.8 Prostacyclin Analogues
1.4.9 Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
1.5 Market by Application
1.5.1 Global Scleroderma Diagnostics and Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Skin Biopsy
1.5.3 Imaging Techniques
1.5.4 Blood Tests
1.5.5 Electrocardiogram and Echocardiogram
1.5.6 Pulmonary Function Tests
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Scleroderma Diagnostics and Therapeutics Market Perspective (2015-2026)
2.2 Global Scleroderma Diagnostics and Therapeutics Growth Trends by Regions
2.2.1 Scleroderma Diagnostics and Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Scleroderma Diagnostics and Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Scleroderma Diagnostics and Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Scleroderma Diagnostics and Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Scleroderma Diagnostics and Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Scleroderma Diagnostics and Therapeutics Players by Market Size
3.1.1 Global Top Scleroderma Diagnostics and Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Scleroderma Diagnostics and Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Scleroderma Diagnostics and Therapeutics Market Concentration Ratio
3.2.1 Global Scleroderma Diagnostics and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Scleroderma Diagnostics and Therapeutics Revenue in 2019
3.3 Scleroderma Diagnostics and Therapeutics Key Players Head office and Area Served
3.4 Key Players Scleroderma Diagnostics and Therapeutics Product Solution and Service
3.5 Date of Enter into Scleroderma Diagnostics and Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Scleroderma Diagnostics and Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Scleroderma Diagnostics and Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020)
5.2 Global Scleroderma Diagnostics and Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Scleroderma Diagnostics and Therapeutics Market Size (2015-2020)
6.2 Scleroderma Diagnostics and Therapeutics Key Players in North America (2019-2020)
6.3 North America Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020)
6.4 North America Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Scleroderma Diagnostics and Therapeutics Market Size (2015-2020)
7.2 Scleroderma Diagnostics and Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020)
7.4 Europe Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Scleroderma Diagnostics and Therapeutics Market Size (2015-2020)
8.2 Scleroderma Diagnostics and Therapeutics Key Players in China (2019-2020)
8.3 China Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020)
8.4 China Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Scleroderma Diagnostics and Therapeutics Market Size (2015-2020)
9.2 Scleroderma Diagnostics and Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020)
9.4 Japan Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Scleroderma Diagnostics and Therapeutics Market Size (2015-2020)
10.2 Scleroderma Diagnostics and Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Scleroderma Diagnostics and Therapeutics Market Size (2015-2020)
11.2 Scleroderma Diagnostics and Therapeutics Key Players in India (2019-2020)
11.3 India Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020)
11.4 India Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Scleroderma Diagnostics and Therapeutics Market Size (2015-2020)
12.2 Scleroderma Diagnostics and Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Actelion Pharmaceuticals, Inc.
13.1.1 Actelion Pharmaceuticals, Inc. Company Details
13.1.2 Actelion Pharmaceuticals, Inc. Business Overview
13.1.3 Actelion Pharmaceuticals, Inc. Scleroderma Diagnostics and Therapeutics Introduction
13.1.4 Actelion Pharmaceuticals, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020))
13.1.5 Actelion Pharmaceuticals, Inc. Recent Development
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Details
13.2.2 Boehringer Ingelheim Business Overview
13.2.3 Boehringer Ingelheim Scleroderma Diagnostics and Therapeutics Introduction
13.2.4 Boehringer Ingelheim Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.2.5 Boehringer Ingelheim Recent Development
13.3 Bayer AG
13.3.1 Bayer AG Company Details
13.3.2 Bayer AG Business Overview
13.3.3 Bayer AG Scleroderma Diagnostics and Therapeutics Introduction
13.3.4 Bayer AG Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.3.5 Bayer AG Recent Development
13.4 Cytori Therapeutics, Inc.
13.4.1 Cytori Therapeutics, Inc. Company Details
13.4.2 Cytori Therapeutics, Inc. Business Overview
13.4.3 Cytori Therapeutics, Inc. Scleroderma Diagnostics and Therapeutics Introduction
13.4.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.4.5 Cytori Therapeutics, Inc. Recent Development
13.5 Cumberland Pharmaceuticals Inc
13.5.1 Cumberland Pharmaceuticals Inc Company Details
13.5.2 Cumberland Pharmaceuticals Inc Business Overview
13.5.3 Cumberland Pharmaceuticals Inc Scleroderma Diagnostics and Therapeutics Introduction
13.5.4 Cumberland Pharmaceuticals Inc Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.5.5 Cumberland Pharmaceuticals Inc Recent Development
13.6 Gilead Sciences, Inc.
13.6.1 Gilead Sciences, Inc. Company Details
13.6.2 Gilead Sciences, Inc. Business Overview
13.6.3 Gilead Sciences, Inc. Scleroderma Diagnostics and Therapeutics Introduction
13.6.4 Gilead Sciences, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.6.5 Gilead Sciences, Inc. Recent Development
13.7 Pfizer, Inc.
13.7.1 Pfizer, Inc. Company Details
13.7.2 Pfizer, Inc. Business Overview
13.7.3 Pfizer, Inc. Scleroderma Diagnostics and Therapeutics Introduction
13.7.4 Pfizer, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.7.5 Pfizer, Inc. Recent Development
13.8 Sanofi
13.8.1 Sanofi Company Details
13.8.2 Sanofi Business Overview
13.8.3 Sanofi Scleroderma Diagnostics and Therapeutics Introduction
13.8.4 Sanofi Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.8.5 Sanofi Recent Development
13.9 Corbus Pharmaceutical Holdings, Inc.
13.9.1 Corbus Pharmaceutical Holdings, Inc. Company Details
13.9.2 Corbus Pharmaceutical Holdings, Inc. Business Overview
13.9.3 Corbus Pharmaceutical Holdings, Inc. Scleroderma Diagnostics and Therapeutics Introduction
13.9.4 Corbus Pharmaceutical Holdings, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.9.5 Corbus Pharmaceutical Holdings, Inc. Recent Development
13.10 F. Hoffmann La Roche Ltd.
13.10.1 F. Hoffmann La Roche Ltd. Company Details
13.10.2 F. Hoffmann La Roche Ltd. Business Overview
13.10.3 F. Hoffmann La Roche Ltd. Scleroderma Diagnostics and Therapeutics Introduction
13.10.4 F. Hoffmann La Roche Ltd. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
13.10.5 F. Hoffmann La Roche Ltd. Recent Development
13.11 Merck KGaA
10.11.1 Merck KGaA Company Details
10.11.2 Merck KGaA Business Overview
10.11.3 Merck KGaA Scleroderma Diagnostics and Therapeutics Introduction
10.11.4 Merck KGaA Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020)
10.11.5 Merck KGaA Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Scleroderma Diagnostics and Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Scleroderma Diagnostics and Therapeutics Revenue
Table 3. Ranking of Global Top Scleroderma Diagnostics and Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Scleroderma Diagnostics and Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Corticosteroids
Table 6. Key Players of Immunosuppressive Agents
Table 7. Key Players of Endothelin Receptor Agonists
Table 8. Key Players of Calcium Channel Blockers
Table 9. Key Players of PDE-5 Inhibitors
Table 10. Key Players of Chelating Agents
Table 11. Key Players of Prostacyclin Analogues
Table 12. Key Players of Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
Table 13. Global Scleroderma Diagnostics and Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 14. Global Scleroderma Diagnostics and Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global Scleroderma Diagnostics and Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global Scleroderma Diagnostics and Therapeutics Market Share by Regions (2015-2020)
Table 17. Global Scleroderma Diagnostics and Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global Scleroderma Diagnostics and Therapeutics Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. Scleroderma Diagnostics and Therapeutics Market Growth Strategy
Table 23. Main Points Interviewed from Key Scleroderma Diagnostics and Therapeutics Players
Table 24. Global Scleroderma Diagnostics and Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 25. Global Scleroderma Diagnostics and Therapeutics Market Share by Players (2015-2020)
Table 26. Global Top Scleroderma Diagnostics and Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Diagnostics and Therapeutics as of 2019)
Table 27. Global Scleroderma Diagnostics and Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players Scleroderma Diagnostics and Therapeutics Product Solution and Service
Table 30. Date of Enter into Scleroderma Diagnostics and Therapeutics Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 33. Global Scleroderma Diagnostics and Therapeutics Market Size Share by Type (2015-2020)
Table 34. Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Type (2021-2026)
Table 35. Global Scleroderma Diagnostics and Therapeutics Market Size Share by Application (2015-2020)
Table 36. Global Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 37. Global Scleroderma Diagnostics and Therapeutics Market Size Share by Application (2021-2026)
Table 38. North America Key Players Scleroderma Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 39. North America Key Players Scleroderma Diagnostics and Therapeutics Market Share (2019-2020)
Table 40. North America Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 41. North America Scleroderma Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 42. North America Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 43. North America Scleroderma Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 44. Europe Key Players Scleroderma Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players Scleroderma Diagnostics and Therapeutics Market Share (2019-2020)
Table 46. Europe Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 47. Europe Scleroderma Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 48. Europe Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 49. Europe Scleroderma Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 50. China Key Players Scleroderma Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 51. China Key Players Scleroderma Diagnostics and Therapeutics Market Share (2019-2020)
Table 52. China Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 53. China Scleroderma Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 54. China Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 55. China Scleroderma Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 56. Japan Key Players Scleroderma Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 57. Japan Key Players Scleroderma Diagnostics and Therapeutics Market Share (2019-2020)
Table 58. Japan Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 59. Japan Scleroderma Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 60. Japan Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 61. Japan Scleroderma Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 62. Southeast Asia Key Players Scleroderma Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 63. Southeast Asia Key Players Scleroderma Diagnostics and Therapeutics Market Share (2019-2020)
Table 64. Southeast Asia Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 65. Southeast Asia Scleroderma Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 66. Southeast Asia Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 67. Southeast Asia Scleroderma Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 68. India Key Players Scleroderma Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 69. India Key Players Scleroderma Diagnostics and Therapeutics Market Share (2019-2020)
Table 70. India Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 71. India Scleroderma Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 72. India Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 73. India Scleroderma Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 74. Central & South America Key Players Scleroderma Diagnostics and Therapeutics Revenue (2019-2020) (Million US$)
Table 75. Central & South America Key Players Scleroderma Diagnostics and Therapeutics Market Share (2019-2020)
Table 76. Central & South America Scleroderma Diagnostics and Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 77. Central & South America Scleroderma Diagnostics and Therapeutics Market Share by Type (2015-2020)
Table 78. Central & South America Scleroderma Diagnostics and Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 79. Central & South America Scleroderma Diagnostics and Therapeutics Market Share by Application (2015-2020)
Table 80. Actelion Pharmaceuticals, Inc. Company Details
Table 81. Actelion Pharmaceuticals, Inc. Business Overview
Table 82. Actelion Pharmaceuticals, Inc. Product
Table 83. Actelion Pharmaceuticals, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 84. Actelion Pharmaceuticals, Inc. Recent Development
Table 85. Boehringer Ingelheim Company Details
Table 86. Boehringer Ingelheim Business Overview
Table 87. Boehringer Ingelheim Product
Table 88. Boehringer Ingelheim Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 89. Boehringer Ingelheim Recent Development
Table 90. Bayer AG Company Details
Table 91. Bayer AG Business Overview
Table 92. Bayer AG Product
Table 93. Bayer AG Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 94. Bayer AG Recent Development
Table 95. Cytori Therapeutics, Inc. Company Details
Table 96. Cytori Therapeutics, Inc. Business Overview
Table 97. Cytori Therapeutics, Inc. Product
Table 98. Cytori Therapeutics, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 99. Cytori Therapeutics, Inc. Recent Development
Table 100. Cumberland Pharmaceuticals Inc Company Details
Table 101. Cumberland Pharmaceuticals Inc Business Overview
Table 102. Cumberland Pharmaceuticals Inc Product
Table 103. Cumberland Pharmaceuticals Inc Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 104. Cumberland Pharmaceuticals Inc Recent Development
Table 105. Gilead Sciences, Inc. Company Details
Table 106. Gilead Sciences, Inc. Business Overview
Table 107. Gilead Sciences, Inc. Product
Table 108. Gilead Sciences, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 109. Gilead Sciences, Inc. Recent Development
Table 110. Pfizer, Inc. Company Details
Table 111. Pfizer, Inc. Business Overview
Table 112. Pfizer, Inc. Product
Table 113. Pfizer, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 114. Pfizer, Inc. Recent Development
Table 115. Sanofi Business Overview
Table 116. Sanofi Product
Table 117. Sanofi Company Details
Table 118. Sanofi Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 119. Sanofi Recent Development
Table 120. Corbus Pharmaceutical Holdings, Inc. Company Details
Table 121. Corbus Pharmaceutical Holdings, Inc. Business Overview
Table 122. Corbus Pharmaceutical Holdings, Inc. Product
Table 123. Corbus Pharmaceutical Holdings, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 124. Corbus Pharmaceutical Holdings, Inc. Recent Development
Table 125. F. Hoffmann La Roche Ltd. Company Details
Table 126. F. Hoffmann La Roche Ltd. Business Overview
Table 127. F. Hoffmann La Roche Ltd. Product
Table 128. F. Hoffmann La Roche Ltd. Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 129. F. Hoffmann La Roche Ltd. Recent Development
Table 130. Merck KGaA Company Details
Table 131. Merck KGaA Business Overview
Table 132. Merck KGaA Product
Table 133. Merck KGaA Revenue in Scleroderma Diagnostics and Therapeutics Business (2015-2020) (Million US$)
Table 134. Merck KGaA Recent Development
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Scleroderma Diagnostics and Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Corticosteroids Features
Figure 3. Immunosuppressive Agents Features
Figure 4. Endothelin Receptor Agonists Features
Figure 5. Calcium Channel Blockers Features
Figure 6. PDE-5 Inhibitors Features
Figure 7. Chelating Agents Features
Figure 8. Prostacyclin Analogues Features
Figure 9. Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.) Features
Figure 10. Global Scleroderma Diagnostics and Therapeutics Market Share by Application: 2020 VS 2026
Figure 11. Skin Biopsy Case Studies
Figure 12. Imaging Techniques Case Studies
Figure 13. Blood Tests Case Studies
Figure 14. Electrocardiogram and Echocardiogram Case Studies
Figure 15. Pulmonary Function Tests Case Studies
Figure 16. Scleroderma Diagnostics and Therapeutics Report Years Considered
Figure 17. Global Scleroderma Diagnostics and Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 18. Global Scleroderma Diagnostics and Therapeutics Market Share by Regions: 2020 VS 2026
Figure 19. Global Scleroderma Diagnostics and Therapeutics Market Share by Regions (2021-2026)
Figure 20. Porter's Five Forces Analysis
Figure 21. Global Scleroderma Diagnostics and Therapeutics Market Share by Players in 2019
Figure 22. Global Top Scleroderma Diagnostics and Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Diagnostics and Therapeutics as of 2019
Figure 23. The Top 10 and 5 Players Market Share by Scleroderma Diagnostics and Therapeutics Revenue in 2019
Figure 24. North America Scleroderma Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Europe Scleroderma Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. China Scleroderma Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Japan Scleroderma Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Southeast Asia Scleroderma Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. India Scleroderma Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Central & South America Scleroderma Diagnostics and Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Bottom-up and Top-down Approaches for This Report
Figure 32. Data Triangulation
Figure 33. Key Executives Interviewed
強皮症治療ソリューションの世界市場（～2026年） Market Analysis and Insights: Global Scleroderma Therapy Solutions Market The global Scleroderma Therapy Solutions market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integ…- 胃食道逆流症（GERD）治療薬の世界市場（～2026年） Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where stomach contents come back up into the esophagus resulting in either symptoms or complications. Patent expiry of blockbuster drugs prescribed for the treatment of acid reflux disorders is majorly attrib…
- 脳卒中診断・治療の世界市場（～2026年） Stroke refers to the brain attack. Stroke occurs when the supply of blood to the brain is either interrupted or reduced. Increasing number of mergers and acquisitions, rapid product launches, and rise in number of collaborations and partnerships are some of the latest trends that have been observed …
- 睡眠時無呼吸診断・治療の世界市場（～2026年） Sleep apnea or Sleep disordered breathing (SDB) is a disorder that is characterised by brief interruptions in breathing or shallow breathing during sleep. Obstructive Sleep Apnea (OSA) is the most common type of sleep apnea.Sleep Apnea Diagnostics and Therapeutics are a serial of methods and medical…
- クラミジア感染症診断・治療の世界市場（～2026年） The chlamydia infection diagnostics and therapeutics market unveils high potential owing to the rapidly rising patient pool and vast untapped opportunities. Market Analysis and Insights: Global Chlamydia Infection Diagnostics and Therapeutics Market The global Chlamydia Infection Diagnostics and The…